Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07721675

Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma

The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

High-grade Serous Ovarian Carcinoma (HGSOC)

Age range

18 year–80 year

Sex eligibility

Female

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.
  • Well-preserved surgical paraffin-embedded tumor specimens.
  • Complete clinical information and survival follow-up data.

Exclusion criteria

  • Received preoperative neoadjuvant treatment.
  • Poor preservation of surgical paraffin specimens.
  • Incomplete clinical information and survival follow-up data.
  • With concurrent malignancies other than high-grade serous ovarian carcinoma.

Treatment and study plan

No Intervention: Observational Cohort

Other

This study is an retrospective observational study. There will be no interventions on the participants.

Primary outcomes

  1. Disease-free survival

    Time frame: through study completion, an average of 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Xiaoming Xing

CONTACT

[email protected]

+8653282911869

Sponsors and collaborators

Lead sponsor

The Affiliated Hospital of Qingdao University

Other

Collaborators

  • Peking University Third Hospital
  • Shandong Provincial Hospital
  • Yantai Yuhuangding Hospital

Registry information

Official study title

Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment

Acronym: AI-PTHGSOC

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 23, 2026
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.